Lupin Pharmaceuticals Inc

Lupin Presents Phase 3 Data for Solosec® (secnidazole) Demonstrating Significant Response Rate in Female Patients with Trichomoniasis

Results presented at the 2020 Infectious Diseases Society for Obstetrics & Gynecology (IDSOG) Virtual Annual Meeting Single-dose treatment with Solosec®…

4 years ago

Lupin Announces Positive Topline Results from its Phase 3 Study of Single-Dose Solosec® (secnidazole) for the Treatment of Trichomoniasis

Primary endpoint successfully achieved in Phase 3 clinical trial of 147 patients Solosec® 2g oral granules was generally well-tolerated among…

4 years ago